Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback